Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors

Purpose: VB-111 is an antiangiogenic agent consisting of a nonreplicating adenovirus vector (Ad-5) with a modified murine pre-proendothelin promoter leading to apoptosis of tumor vasculature by expressing a Fas-chimera transgene in angiogenic endothelial cells. In a phase I dose-escalation study, pharmacokinetics, pharmacodynamics, safety, and efficacy of a single dose of VB-111 in patients with advanced solid tumors were evaluated. Experimental Design: VB-111 was administered as a single i.v. infusion at escalating doses from 1 × 1010 (cohort 1) to 1 × 1013 (cohort 7) viral particles (VP) in successive cohorts. Assessments included pharmacokinetic and pharmacodynamic profiles, tumor response, and overall survival. Results: Thirty-three patients were enrolled. VB-111 was safe and well-tolerated; self-limited fever and chills were seen at doses above 3 × 1011 VPs. Transgene expression was not detected in blood but was detected in an aspirate from a subcutaneous metastasis after treatment. One patient with papillary thyroid carcinoma had a partial response. Conclusions: VB-111 was safe and well tolerated in patients with advanced metastatic cancer at a single administration of up to 1 × 1013 VPs. Evidence of transgene expression in tumor tissue and tumor response was observed. Clin Cancer Res; 19(14); 3996–4007. ©2013 AACR.

[1]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[2]  I. Barshack,et al.  Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect , 2008, Cancer Gene Therapy.

[3]  K. Hall,et al.  Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. , 2010, The Biochemical journal.

[4]  S. Seaman,et al.  Genes that distinguish physiological and pathological angiogenesis. , 2007, Cancer cell.

[5]  A Afek,et al.  Tissue-specific gene therapy directed to tumor angiogenesis , 2001, Gene Therapy.

[6]  D. Harats,et al.  Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. , 1995, The Journal of clinical investigation.

[7]  Y. Naomoto,et al.  Adenovirus-mediated cancer gene therapy and virotherapy (Review). , 2009, International journal of molecular medicine.

[8]  I. Uthman,et al.  Viral infections and antiphospholipid antibodies. , 2002, Seminars in arthritis and rheumatism.

[9]  Andrew Brenner,et al.  Abstract 5400: Antiangiogenic gene therapy with VB111 is active in glioblastoma xenografts , 2011 .

[10]  V. Margulis,et al.  Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. , 2005, Urology.

[11]  J. Camonis,et al.  Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects (*) , 1995, The Journal of Biological Chemistry.

[12]  A. Deisseroth,et al.  Tumor vascular targeting therapy with viral vectors. , 2006, Blood.

[13]  I. Barshack,et al.  Transcription-controlled gene therapy against tumor angiogenesis. , 2004, The Journal of clinical investigation.

[14]  Yihai Cao,et al.  Optimizing the Delivery of Cancer Drugs That Block Angiogenesis , 2010, Science Translational Medicine.

[15]  J. Nör,et al.  Transcriptional targeting of tumor endothelial cells for gene therapy. , 2009, Advanced drug delivery reviews.

[16]  M. Ozawa,et al.  Ligand-directed Cancer Gene Therapy to Angiogenic Vasculature , 2009, Advances in Genetics.

[17]  A. Hemminki,et al.  Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. , 2011, Molecular pharmaceutics.

[18]  Y. Cohen,et al.  Abstract 3283: VB-111 a novel anti-angiogenic vector and a promising treatment for metastatic cancer in combination with other anticancer drugs , 2011 .

[19]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[20]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[21]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[22]  S. Weger,et al.  Viral vectors for gene transfer: current status of gene therapeutics. , 2010, Handbook of experimental pharmacology.